In a move aimed at improving affordability and accessibility, the Centre has revised the prices of 71 essential drug formulations, including those used to treat metastatic breast cancer, diabetes, peptic ulcers, and severe infections. The new prices were announced by the National Pharmaceutical Pricing Authority (NPPA) through an official notification.
Key Cancer, Ulcer, and Infection Drugs Covered
Among the key drugs listed is Trastuzumab, used in treating metastatic breast and gastric cancer, manufactured by Reliance Life Sciences. Its price has been capped at Rs 11,966 per vial.
A combination tablet containing clarithromycin, esomeprazole, and amoxicillin — used for treating peptic ulcer disease and made by Torrent Pharmaceuticals — will now cost Rs 162.5 per tablet.
A combipack containing ceftriaxone, disodium edetate, and sulbactam powder for treating life-threatening infections has been priced at Rs 626 per vial. A similar combination drug from Tyykem, in powder form for infusion, will now cost Rs 515.5 per vial.
Price Cuts for Antidiabetic Medications
The revised list includes 25 antidiabetic formulations containing sitagliptin, along with several fixed-dose combinations featuring empagliflozin, reflecting a strong push to make diabetes care more affordable.
Ensuring Transparency and Affordability
The NPPA, which regulates the ceiling prices of essential medicines in India, had earlier directed pharmaceutical companies to share updated price lists with dealers, state drug controllers, and government bodies — a move aimed at enhancing transparency.
The latest notification reinforces NPPA’s commitment to regulating the cost of critical medicines and reducing the financial burden on patients. By capping prices, especially of life-saving drugs, the initiative supports India’s broader healthcare equity and affordability goals.
